AOP-208 / AOP Orphan Pharma, Leukos Biotech - LARVOL DELTA

LB-208/AOP208 a first-in-class HTR1B antagonist: First-in-human, dose finding phase I study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity in adult patients with relapsed or refractory solid tumors or lymphoma (ESMO 2025) - "Clinical trial identification 2023-509532-25-00. Legal entity responsible for the study Leukos Biotech, S.L. Funding Leukos Biotech, S.L."

Clinical • First-in-human • P1 data • PK/PD data • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results (Businesswire) - "SERONCO-1, a phase I, first-in-human trial in patients with solid tumors and lymphomas will be conducted in collaboration with Leukos Biotech at the Vall d’Hebron Institute of Oncology (VHIO) with partial funding from the Spanish Ministry of Science and Innovation through the Public-Private Partnership Program (CPP2021-008715). A subsequent trial in acute myeloid leukemia is expected to commence in 2026."

New trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology